HC Wainwright Has Positive View of OPKO Health Q2 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Equities researchers at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of OPKO Health in a research note issued on Wednesday, March 12th. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s FY2025 earnings at ($0.30) EPS.

Several other equities analysts also recently weighed in on the company. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Barrington Research reaffirmed an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Wednesday, March 12th.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.79 on Monday. OPKO Health has a 1-year low of $0.86 and a 1-year high of $2.04. The company has a market capitalization of $1.20 billion, a P/E ratio of -9.42 and a beta of 1.70. The business has a 50 day moving average price of $1.63 and a 200 day moving average price of $1.57. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently made changes to their positions in OPK. Wealth Enhancement Advisory Services LLC lifted its position in OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,417 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in OPKO Health by 24.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 753,380 shares of the biotechnology company’s stock worth $1,107,000 after purchasing an additional 148,322 shares during the period. Two Sigma Advisers LP lifted its position in OPKO Health by 2.3% in the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,396 shares during the period. Two Sigma Investments LP lifted its position in OPKO Health by 136.1% in the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock worth $2,422,000 after purchasing an additional 949,671 shares during the period. Finally, ProShare Advisors LLC lifted its position in OPKO Health by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 91,730 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 30,182 shares during the period. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock in a transaction dated Tuesday, January 28th. The stock was acquired at an average cost of $1.47 per share, for a total transaction of $69,879.39. Following the completion of the transaction, the chief executive officer now owns 213,234,014 shares in the company, valued at approximately $313,454,000.58. This represents a 0.02 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders bought a total of 964,971 shares of company stock valued at $1,493,692 over the last three months. 47.26% of the stock is owned by insiders.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.